Alterity Therapeutics (NASDAQ:ATHE) Now Covered by Analysts at Craig Hallum

Research analysts at Craig Hallum started coverage on shares of Alterity Therapeutics (NASDAQ:ATHE) in a research note issued to investors on Tuesday. The firm set a “buy” rating and a $12.00 price target on the stock. Craig Hallum’s price objective indicates a potential upside of 161.84% from the company’s current price.

Other research analysts have also issued research reports about the stock. Zacks Research raised shares of Alterity Therapeutics to a “hold” rating in a research report on Wednesday, June 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Friday, July 17th. JonesTrading assumed coverage on Alterity Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $16.00 price target on the stock. Finally, LADENBURG THALM/SH SH began coverage on Alterity Therapeutics in a report on Tuesday, June 16th. They issued a “buy” rating and a $10.00 price target for the company. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Alterity Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $12.67.

Alterity Therapeutics Price Performance

Shares of Alterity Therapeutics stock opened at $4.58 on Tuesday. The firm has a fifty day moving average price of $4.76 and a two-hundred day moving average price of $4.13. Alterity Therapeutics has a fifty-two week low of $2.66 and a fifty-two week high of $5.89.

Institutional Investors Weigh In On Alterity Therapeutics

A hedge fund recently bought a new position in Alterity Therapeutics stock. Citadel Advisors LLC acquired a new stake in shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.25% of Alterity Therapeutics at the end of the most recent quarter. 2.14% of the stock is owned by institutional investors and hedge funds.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.